Search Results - philip+alex

2 Results

Sort By:

Inflammatory Bowel Disease (IBD): New Cytokine Biomarkers

C10931: Markers for Diagnosis and/or Prognosis of Irritable Bowel Disease and Syndrome Value Proposition: - The identified markers may be combined to optimize sensitivity and specificity. - These markers may be used in ELISA or Chip format. - Markers have been validated using colonic tissue biopsy samples. - Predicate technology and CPT codes already...

Published: 7/4/2024 | Inventor(s): Michael Centola, Nicholas Knowlton, Xuhang Li, Philip Alex

Keywords(s): Biomarker, Chronic Inflammatory Diseases, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, Gastrointestinal Disorders, In Vitro Diagnostics, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD)

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease, Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Inflammation

PNU-120596 and 3-(2,4-dimethoxybenzylidene) Anabaseine (GTS-21) (both nAchRa7 agonists) and Methyllycaconitine (anAchRa7 antagonist), are Highly Effective Drugs in Therapy of Ulcerative Colitis (UC) and Crohn's Disease (CD)

C10382: Breakthrough Therapeutic for Inflammatory Bowel Diseases (IBD)Novelty: This technology identifies a nicotinic acetylcholine receptor isoform (nAChR7) that has a prevalent role in affecting Inflammatory Bowel Disease (IBD), as well as several agonist/antagonists to nAChR7, that are highly effective in both the prevention and therapy of ulcerative...

Published: 7/4/2024 | Inventor(s): Philip Alex, Michael Centola, Xuhang Li

Keywords(s): Chronic Inflammatory Diseases, Combination, Crohn's disease, Crohn's Disease, Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD), Natural compounds, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Ulcerative Colitis, Ulcerative Colitis (UC)